Protagonist Therapeutics

Yahoo Finance • 5 days ago

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results further support the differentiated profil... Full story

Yahoo Finance • 6 days ago

Do Protagonist Therapeutics’ (PTGX) Derisked Drugs Have Blockbuster Potential?

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the Russell 2000 Growth Index... Full story

Yahoo Finance • 8 days ago

US High Growth Tech Stocks to Watch Now

Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings expected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companie... Full story

Yahoo Finance • 11 days ago

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

Key Points RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW... Full story

Yahoo Finance • 11 days ago

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story

Yahoo Finance • 15 days ago

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met all primary endpoints and demonstrate... Full story

Yahoo Finance • 25 days ago

FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug Application and granted Priority Review for rus... Full story

Yahoo Finance • last month

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expe... Full story

Yahoo Finance • last month

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day... Full story

Yahoo Finance • last month

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance

On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics(NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of approximately $1.7 million, according to a SEC Form... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The f... Full story

Yahoo Finance • 2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

As February begins, the U.S. stock market has shown a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting positive sentiment despite recent economic uncertainties such as delayed jobs report... Full story

Yahoo Finance • 4 months ago

Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera

(RTTNews) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV). The data, presented at the 67th American Society... Full story

Yahoo Finance • 4 months ago

Protagonist Therapeutics Reaches Analyst Target Price

In recent trading, shares of Protagonist Therapeutics Inc (Symbol: PTGX) have crossed above the average analyst 12-month target price of $89.77, changing hands for $89.86/share. When a stock reaches the target an analyst has set, the anal... Full story

Yahoo Finance • 5 months ago

Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial

Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 months ago

Protagonist Therapeutics falls amid a report J&J deal price may be lower

[Johnson & Johnson offices in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]) dropped 5% after a report that the Johnson & Johnson (NYSE:JN... Full story

Yahoo Finance • 6 months ago

J&J in talks to acquire Protagonist Therapeutics

Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, a move that would enhance their current collaboration, as reported by The Wall Street Journal (WSJ). While a deal is not certain, the acquisition could signif... Full story

Yahoo Finance • 6 months ago

Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more

Here's a list of key deals reported across sectors this week: * Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall... Full story

Yahoo Finance • 6 months ago

Protagonist Stock Surges on Johnson & Johnson Report

Protagonist Therapeutics shares soared more than 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more ... Continue Reading Visualizza comme... Full story

Yahoo Finance • 6 months ago

Trump's China tariff threat sinks stocks, Applied Digital surges

Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition... Full story